Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC)

被引：11

作者：

McCarthy, Fiona ^{[1
]}

Roshani, Rozita ^{[1
]}

Steele, Jeremy ^{[2
]}

Hagemann, Thorsten ^{[1
]}

机构：

[1] Univ London, Ctr Canc & Inflammat, Barts Canc Inst, John Vane Sci Ctr, London EC1M 6BQ, England

[2] St Bartholomews Hosp, London, England

来源：

JOURNAL OF LEUKOCYTE BIOLOGY | 2013年 / 94卷 / 06期

关键词：

immunotherapeutic agents; malignancies; tumor; progression-free survival; CD8(+) T-CELLS; PROGNOSTIC-FACTOR; VACCINE; STAGE; MUC1; EXPRESSION; INFILTRATION; ANTIBODY; HETEROGENEITY; CHEMOTHERAPY;

D O I：

10.1189/jlb.0313121

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Review of current immunotherapeutic approaches in the treatment of non-small cell lung cancer. NSCLC remains one of the most challenging malignancies to treat. Despite the introduction of innovative therapies over the last decade, the 5-year survival of NSCLC is still <20%. Clearly, novel, therapeutic approaches are required. Targeting the immune system to derive meaningful clinical benefit has proved successful in various malignancies in recent years. As a result, there is renewed focus on the use of immunotherapy in lung cancer. In this review, we provide an overview of current immune-modulatory approaches in the treatment of NSCLC.

引用

页码：1201 / 1206

页数：6

共 55 条

[31] The blockade of immune checkpoints in cancer immunotherapy [J].

Pardoll, Drew M. .

NATURE REVIEWS CANCER, 2012, 12 (04) :252-264

[32] Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients [J].

Petersen, Rebecca P. ;

Carnpa, Michael J. ;

Sperlazza, Justin ;

Conlon, Debbi ;

Joshi, Mary-Beth ;

Harpole, David H., Jr. ;

Patz, Edward F., Jr. .

CANCER, 2006, 107 (12) :2866-2872

[33] Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial [J].

Quoix, Elisabeth ;

Ramlau, Rodryg ;

Westeel, Virginie ;

Papai, Zsolt ;

Madroszyk, Anne ;

Riviere, Alain ;

Koralewski, Piotr ;

Breton, Jean-Luc ;

Stoelben, Erich ;

Braun, Denis ;

Debieuvre, Didier ;

Lena, Herve ;

Buyse, Marc ;

Chenard, Marie-Pierre ;

Acres, Bruce ;

Lacoste, Gisele ;

Bastien, Berangere ;

Tavernaro, Annette ;

Bizouarne, Nadine ;

Bonnefoy, Jean-Yves ;

Limacher, Jean-Marc .

LANCET ONCOLOGY, 2011, 12 (12) :1125-1133

[34] MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1 [J].

Rahn, JJ ;

Chow, JW ;

Horne, GJ ;

Mah, BK ;

Emerman, JT ;

Hoffman, P ;

Hugh, JC .

CLINICAL & EXPERIMENTAL METASTASIS, 2005, 22 (06) :475-483

[35] What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? [J].

Reck, M. .

ANNALS OF ONCOLOGY, 2012, 23 :28-34

[36]

Regimbald LH, 1996, CANCER RES, V56, P4244

[37] Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [J].

Robert, Caroline ;

Thomas, Luc ;

Bondarenko, Igor ;

O'Day, Steven ;

Weber, Jeffrey ;

Garbe, Claus ;

Lebbe, Celeste ;

Baurain, Jean-Francois ;

Testori, Alessandro ;

Grob, Jean-Jacques ;

Davidson, Neville ;

Richards, Jon ;

Maio, Michele ;

Hauschild, Axel ;

Miller, Wilson H., Jr. ;

Gascon, Pere ;

Lotem, Michal ;

Harmankaya, Kaan ;

Ibrahim, Ramy ;

Francis, Stephen ;

Chen, Tai-Tsang ;

Humphrey, Rachel ;

Hoos, Axel ;

Wolchok, Jedd D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2517-2526

[38]

Rodriguez PC, 2010, MEDICC REV, V12, P17, DOI 10.37757/MR2010.V12.N1.4

[39]

Samuel J, 1998, INT J CANCER, V75, P295, DOI 10.1002/(SICI)1097-0215(19980119)75:2<295::AID-IJC20>3.0.CO

[40]

2-B

← 1 2 3 4 5 6 →